JP2005500039A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005500039A5 JP2005500039A5 JP2003509084A JP2003509084A JP2005500039A5 JP 2005500039 A5 JP2005500039 A5 JP 2005500039A5 JP 2003509084 A JP2003509084 A JP 2003509084A JP 2003509084 A JP2003509084 A JP 2003509084A JP 2005500039 A5 JP2005500039 A5 JP 2005500039A5
- Authority
- JP
- Japan
- Prior art keywords
- tim
- polypeptide
- individual
- predisposing
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100034459 Hepatitis A virus cellular receptor 1 Human genes 0.000 claims 24
- 238000000034 method Methods 0.000 claims 24
- 229920001184 polypeptide Polymers 0.000 claims 19
- 102000004196 processed proteins & peptides Human genes 0.000 claims 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims 19
- 102100039367 T-cell immunoglobulin and mucin domain-containing protein 4 Human genes 0.000 claims 11
- 150000007523 nucleic acids Chemical class 0.000 claims 11
- JPSHPWJJSVEEAX-OWPBQMJCSA-N (2s)-2-amino-4-fluoranylpentanedioic acid Chemical compound OC(=O)[C@@H](N)CC([18F])C(O)=O JPSHPWJJSVEEAX-OWPBQMJCSA-N 0.000 claims 10
- 108010007712 Hepatitis A Virus Cellular Receptor 1 Proteins 0.000 claims 10
- 101710174757 T-cell immunoglobulin and mucin domain-containing protein 4 Proteins 0.000 claims 10
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims 10
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 9
- 108020004707 nucleic acids Proteins 0.000 claims 9
- 102000039446 nucleic acids Human genes 0.000 claims 9
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims 8
- 239000003795 chemical substances by application Substances 0.000 claims 8
- 239000000523 sample Substances 0.000 claims 8
- 101150022210 tim gene Proteins 0.000 claims 7
- 208000026278 immune system disease Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 102000043124 TIM family Human genes 0.000 claims 3
- 108091054435 TIM family Proteins 0.000 claims 3
- 239000013543 active substance Substances 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 108020001507 fusion proteins Proteins 0.000 claims 3
- 102000037865 fusion proteins Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000009870 specific binding Effects 0.000 claims 2
- 238000011820 transgenic animal model Methods 0.000 claims 2
- 108700028369 Alleles Proteins 0.000 claims 1
- 208000012657 Atopic disease Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 101001068136 Homo sapiens Hepatitis A virus cellular receptor 1 Proteins 0.000 claims 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims 1
- 101000669511 Homo sapiens T-cell immunoglobulin and mucin domain-containing protein 4 Proteins 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 101100284387 Mus musculus Havcr1 gene Proteins 0.000 claims 1
- 101001068132 Mus musculus Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims 1
- 101000669558 Mus musculus T-cell immunoglobulin and mucin domain-containing protein 2 Proteins 0.000 claims 1
- 101000669510 Mus musculus T-cell immunoglobulin and mucin domain-containing protein 4 Proteins 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 101710174876 Probable triosephosphate isomerase 2 Proteins 0.000 claims 1
- 101710174758 T-cell immunoglobulin and mucin domain-containing protein 2 Proteins 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940000406 drug candidate Drugs 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 238000003209 gene knockout Methods 0.000 claims 1
- 102000051539 human HAVCR1 Human genes 0.000 claims 1
- 102000049109 human HAVCR2 Human genes 0.000 claims 1
- 102000045158 human TIMD4 Human genes 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
Images
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30234401P | 2001-06-29 | 2001-06-29 | |
| PCT/US2002/020890 WO2003002722A2 (en) | 2001-06-29 | 2002-07-01 | T cell regulatory genes and methods of use thereof |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006211500A Division JP4351233B2 (ja) | 2001-06-29 | 2006-08-02 | Ｔ細胞調節遺伝子およびその使用方法 |
| JP2009239582A Division JP2010057492A (ja) | 2001-06-29 | 2009-10-16 | Ｔ細胞調節遺伝子およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005500039A JP2005500039A (ja) | 2005-01-06 |
| JP2005500039A5 true JP2005500039A5 (enExample) | 2006-09-21 |
| JP4572276B2 JP4572276B2 (ja) | 2010-11-04 |
Family
ID=23167357
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003509084A Expired - Fee Related JP4572276B2 (ja) | 2001-06-29 | 2002-07-01 | Ｔ細胞調節遺伝子およびその使用方法 |
| JP2006211500A Expired - Fee Related JP4351233B2 (ja) | 2001-06-29 | 2006-08-02 | Ｔ細胞調節遺伝子およびその使用方法 |
| JP2009239582A Withdrawn JP2010057492A (ja) | 2001-06-29 | 2009-10-16 | Ｔ細胞調節遺伝子およびその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006211500A Expired - Fee Related JP4351233B2 (ja) | 2001-06-29 | 2006-08-02 | Ｔ細胞調節遺伝子およびその使用方法 |
| JP2009239582A Withdrawn JP2010057492A (ja) | 2001-06-29 | 2009-10-16 | Ｔ細胞調節遺伝子およびその使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7553939B2 (enExample) |
| EP (1) | EP1406653A4 (enExample) |
| JP (3) | JP4572276B2 (enExample) |
| KR (1) | KR20040014997A (enExample) |
| CN (1) | CN1538853A (enExample) |
| CA (1) | CA2452196A1 (enExample) |
| IL (1) | IL159627A0 (enExample) |
| MX (1) | MXPA04000034A (enExample) |
| NZ (1) | NZ530451A (enExample) |
| WO (1) | WO2003002722A2 (enExample) |
| ZA (1) | ZA200400013B (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997044460A1 (en) * | 1996-05-24 | 1997-11-27 | Biogen, Inc. | Modulators of tissue regeneration |
| WO2001098481A2 (en) * | 2000-06-16 | 2001-12-27 | Biogen, Inc. | Renal regulatory elements and methods of use thereof |
| AU2002305785B2 (en) * | 2001-06-01 | 2008-01-17 | Biogen Ma Inc. | Molecules and methods for inhibiting shedding of KIM-1 |
| EP1406653A4 (en) * | 2001-06-29 | 2005-05-04 | Univ Leland Stanford Junior | T CELL REGULATION GENES AND METHOD OF USE THEREOF |
| US8709412B2 (en) | 2001-06-29 | 2014-04-29 | The Board Of Trustees Of The Leland Stanford Junior University | Modulation of TIM receptor activity in combination with cytoreductive therapy |
| US7838220B2 (en) | 2001-06-29 | 2010-11-23 | The Board Of Trustees Of The Leland Stanford Junior University | T cell regulatory genes associated with immune disease |
| AU2003303082B2 (en) | 2002-01-30 | 2009-07-02 | Dana-Farber Cancer Institute, Inc. | Compositions and methods related to TIM-3, a Th1-specific cell surface molecule |
| EP1576169B1 (en) * | 2002-03-19 | 2016-08-10 | Celldex Therapeutics, Inc. | Therapeutic polypeptides and methods of use |
| PT1585546E (pt) * | 2002-12-30 | 2008-11-14 | Biogen Idec Inc | Antagonistas de kim-1 e sua utilização para modular o sistema imunitário |
| AU2013242840B2 (en) * | 2003-03-19 | 2017-01-19 | Amgen Fremont Inc. | Antibodies Against T Cell Immunoglobulin Domain and Mucin Domain 1 (TIM-1) Antigen and Uses Thereof |
| JP2007525434A (ja) * | 2003-03-19 | 2007-09-06 | アブジェニックス インコーポレイテッド | Ｔ細胞、免疫グロブリンドメインおよびムチンドメイン１（ｔｉｍ−１）抗原に対する抗体およびその使用。 |
| BRPI0414924A (pt) | 2003-10-03 | 2006-11-07 | Brigham & Womens Hospital | ligantes de tim-3 e seus métodos |
| US20050197292A1 (en) * | 2004-01-30 | 2005-09-08 | Glennda Smithson | Compositions and methods for treating T-cell mediated pathological conditions |
| TW200539890A (en) * | 2004-03-12 | 2005-12-16 | Brigham & Womens Hospital | Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function |
| EA200601761A1 (ru) * | 2004-03-24 | 2007-06-29 | Телос Фармасьютикалз, Инк. | Композиции в качестве адъювантов для усиления иммунных ответов на вакцины и способы их применения |
| EP2290071B1 (en) | 2004-05-28 | 2014-12-31 | Asuragen, Inc. | Methods and compositions involving microRNA |
| EP2314688B1 (en) | 2004-11-12 | 2014-07-16 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
| CN1778816B (zh) * | 2004-11-22 | 2010-07-07 | 中国人民解放军第二军医大学 | 人细胞表面膜分子及用途 |
| EP1865985B1 (en) * | 2005-03-02 | 2010-08-25 | Biogen Idec MA Inc. | Kim-1 antibodies for treatment of th2-mediated conditions |
| KR100746312B1 (ko) * | 2005-03-14 | 2007-08-03 | 한국화학연구원 | 수용성 산화철 나노 입자 및 이의 제조방법 |
| AU2007299828C1 (en) * | 2006-09-19 | 2014-07-17 | Interpace Diagnostics, Llc | MicroRNAs differentially expressed in pancreatic diseases and uses thereof |
| WO2009036332A1 (en) | 2007-09-14 | 2009-03-19 | Asuragen, Inc. | Micrornas differentially expressed in cervical cancer and uses thereof |
| WO2009070805A2 (en) | 2007-12-01 | 2009-06-04 | Asuragen, Inc. | Mir-124 regulated genes and pathways as targets for therapeutic intervention |
| WO2009111643A2 (en) * | 2008-03-06 | 2009-09-11 | Asuragen, Inc. | Microrna markers for recurrence of colorectal cancer |
| EP2285960B1 (en) | 2008-05-08 | 2015-07-08 | Asuragen, INC. | Compositions and methods related to mir-184 modulation of neovascularization or angiogenesis |
| WO2010095461A1 (ja) * | 2009-02-20 | 2010-08-26 | 国立大学法人東京大学 | 新規モノクローナル抗体、並びにその使用 |
| WO2013040251A2 (en) | 2011-09-13 | 2013-03-21 | Asurgen, Inc. | Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease |
| JP6196034B2 (ja) * | 2012-12-20 | 2017-09-13 | ライオン株式会社 | 高血糖リスク判定用マーカーペプチドおよびその用途 |
| EP3757130A1 (en) | 2013-09-26 | 2020-12-30 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| ME03558B (me) | 2014-03-14 | 2020-07-20 | Novartis Ag | Molekuli anti-lag-3 antiтela i njihove upotrebe |
| KR20170060042A (ko) | 2014-09-13 | 2017-05-31 | 노파르티스 아게 | Alk 억제제의 조합 요법 |
| EP3283508B1 (en) | 2015-04-17 | 2021-03-17 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins with tunable affinities |
| TWI726920B (zh) * | 2015-10-14 | 2021-05-11 | 耶魯大學 | 基因體規模的ｔ細胞活性陣列、其製造方法、其用於辨識免疫調節因子的方法及其用途 |
| KR102824067B1 (ko) | 2016-04-15 | 2025-06-23 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Icos 리간드 변이체 면역조절 단백질 및 그의 용도 |
| MA45123A (fr) | 2016-05-27 | 2019-04-10 | Agenus Inc | Anticorps anti-tim-3 et leurs méthodes d'utilisation |
| AU2017297506A1 (en) | 2016-07-14 | 2019-02-21 | Bristol-Myers Squibb Company | Antibodies against TIM3 and uses thereof |
| WO2018036561A1 (en) * | 2016-08-26 | 2018-03-01 | Beigene, Ltd. | Anti-tim-3 antibodies and use thereof |
| US20200055917A1 (en) | 2016-09-27 | 2020-02-20 | Cero Therapeutics, Inc. | Chimeric engulfment receptor molecules |
| WO2018086594A1 (en) | 2016-11-11 | 2018-05-17 | Beijing Biocytogen Co., Ltd | Genetically modified non-human animal with human or chimeric tim-3 |
| CN111533796A (zh) * | 2017-04-10 | 2020-08-14 | 伊玛提克斯生物技术有限公司 | 用于癌症免疫治疗的肽及其肽组合物 |
| FI3688032T3 (fi) | 2017-09-26 | 2025-12-09 | Cero Therapeutics Holdings Inc | Kimeerisiä nielaisureseptorimolekyylejä ja käyttömenetelmiä |
| CN108037292A (zh) * | 2017-11-29 | 2018-05-15 | 天津市湖滨盘古基因科学发展有限公司 | 一种人的磷脂酰丝氨酸受体突变蛋白及其应用 |
| EP3774906A1 (en) | 2018-03-28 | 2021-02-17 | Cero Therapeutics, Inc. | Chimeric tim4 receptors and uses thereof |
| AU2019243154A1 (en) | 2018-03-28 | 2020-10-01 | Cero Therapeutics, Inc. | Cellular immunotherapy compositions and uses thereof |
| CN110412263B (zh) * | 2019-07-31 | 2023-01-31 | 中国农业科学院茶叶研究所 | 一种快速高效的茶树质体型谷氨酰胺合成酶基因定位方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6066322A (en) * | 1995-03-03 | 2000-05-23 | Millennium Pharmaceuticals, Inc. | Methods for the treatment of immune disorders |
| WO1997044460A1 (en) * | 1996-05-24 | 1997-11-27 | Biogen, Inc. | Modulators of tissue regeneration |
| US5986059A (en) * | 1996-06-14 | 1999-11-16 | Bayer Corporation | T-cell selective interleukin-4 agonists |
| WO1999038881A1 (en) | 1998-01-30 | 1999-08-05 | Human Genome Sciences, Inc. | 67 human secreted proteins |
| US7060458B1 (en) * | 1997-08-14 | 2006-06-13 | Wyeth | Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics |
| EP1064360B1 (en) * | 1998-03-27 | 2008-03-05 | Prolume, Ltd. | Luciferases, gfp fluorescent proteins, their nucleic acids and the use thereof in diagnostics |
| WO2002081517A2 (en) * | 2001-01-19 | 2002-10-17 | Curagen Corporation | Novel polypeptides and nucleic acids encoded thereby |
| EP1406653A4 (en) * | 2001-06-29 | 2005-05-04 | Univ Leland Stanford Junior | T CELL REGULATION GENES AND METHOD OF USE THEREOF |
-
2002
- 2002-07-01 EP EP02748027A patent/EP1406653A4/en not_active Withdrawn
- 2002-07-01 US US10/188,012 patent/US7553939B2/en not_active Expired - Fee Related
- 2002-07-01 JP JP2003509084A patent/JP4572276B2/ja not_active Expired - Fee Related
- 2002-07-01 CA CA002452196A patent/CA2452196A1/en not_active Abandoned
- 2002-07-01 KR KR10-2003-7003079A patent/KR20040014997A/ko not_active Ceased
- 2002-07-01 IL IL15962702A patent/IL159627A0/xx unknown
- 2002-07-01 NZ NZ530451A patent/NZ530451A/en unknown
- 2002-07-01 CN CNA028130154A patent/CN1538853A/zh active Pending
- 2002-07-01 WO PCT/US2002/020890 patent/WO2003002722A2/en not_active Ceased
- 2002-07-01 MX MXPA04000034A patent/MXPA04000034A/es unknown
-
2004
- 2004-01-05 ZA ZA200400013A patent/ZA200400013B/en unknown
-
2006
- 2006-08-02 JP JP2006211500A patent/JP4351233B2/ja not_active Expired - Fee Related
-
2009
- 2009-06-16 US US12/485,765 patent/US20090252737A1/en not_active Abandoned
- 2009-10-16 JP JP2009239582A patent/JP2010057492A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005500039A5 (enExample) | ||
| Gawel et al. | A validated single-cell-based strategy to identify diagnostic and therapeutic targets in complex diseases | |
| Krainer et al. | Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer | |
| Hengel et al. | Cutting edge: L-selectin (CD62L) expression distinguishes small resting memory CD4+ T cells that preferentially respond to recall antigen | |
| Liu et al. | New signaling pathways govern the host response to C. albicans infection in various niches | |
| ES2424269T3 (es) | Inmuno-PCR sándwich por desplazamiento | |
| JP2016536002A (ja) | 抗ｔｌ１ａ療法のためのシステム、デバイス、及び方法 | |
| Davar et al. | Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial | |
| Rodríguez-Carrio et al. | IRF4 and IRGs delineate clinically relevant gene expression signatures in systemic lupus erythematosus and rheumatoid arthritis | |
| Nouri et al. | Predicting treatment response to IL6R blockers in rheumatoid arthritis | |
| Delord et al. | High imatinib dose overcomes insufficient response associated with ABCG2 haplotype in chronic myelogenous leukemia patients | |
| Mulla et al. | Association of interferon gamma inducible protein-10, monocyte chemoattractant protein-1, macrophage inflammatory protein-1 alpha, interleukin-6, and rs12252 single nucleotide polymorphism of interferon-induced transmembrane protein-3 gene with the severity of COVID-19 infection | |
| CN110004149A (zh) | 一种程序性死亡受体-配体1的核酸适体及其应用 | |
| JP2024509576A (ja) | 明細胞腎細胞がんを有する患者における治療に対する応答の予測 | |
| Moioli et al. | Genomic scan for identifying candidate genes for paratuberculosis resistance in sheep | |
| JP2004533825A5 (enExample) | ||
| Luo et al. | Integrated computational analysis identifies therapeutic targets with dual action in cancer cells and T cells | |
| Fang et al. | Application of comparative transcriptional genomics to identify molecular targets for pediatric IBD | |
| Meugnier et al. | Gene expression profiling in peripheral blood cells of patients with rheumatoid arthritis in response to anti-TNF-α treatments | |
| EP3574114B1 (en) | Biomarkers for systemic lupus erythematosus disease activity, and intensity and flare | |
| Srinivas et al. | Single-cell RNA and T-cell receptor sequencing unveil mycosis fungoides heterogeneity and a possible gene signature | |
| Montagne et al. | CD137 agonism enhances anti-PD1 induced activation of expanded CD8+ T cell clones in a neoadjuvant pancreatic cancer clinical trial | |
| Ma et al. | Attenuated IL-2 muteins leverage the TCR signal to enhance regulatory T cell homeostasis and response in vivo | |
| Liao et al. | How single-cell techniques help us look into lung cancer heterogeneity and immunotherapy | |
| Goertsches et al. | Sieving treatment biomarkers from blood gene-expression profiles: a pharmacogenomic update on two types of multiple sclerosis therapy |